Trials / Unknown
UnknownNCT05085626
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
An Open, Multi-center, Cohort Clinical Study of Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive and HER2-negative Advanced Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fluzoparib+chidamide | Arms A will be treated with fluzoparib in combination with cedaramide |
| DRUG | fluzoparib+camrelizumab | Arms B will be treated with fluzoparib in combination with camrelizumab |
Timeline
- Start date
- 2021-02-08
- Primary completion
- 2023-10-31
- Completion
- 2024-12-31
- First posted
- 2021-10-20
- Last updated
- 2022-09-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05085626. Inclusion in this directory is not an endorsement.